Treatment of b-cell malignancies

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 39/395 (2006.01)

Patent

CA 2595398

The present invention generally relates to a pharmaceutical composition and to an improved method of preventing, attenuating and treating multiple myeloma (MM) by administering to an individual in need thereof at least one antibody to fibroblast growth factor receptor 3 (FGFR3). In particular, the at least one FGR3 antibody induces apoptosis of myeloma cells expressing wild type FGFR3.

L'invention se rapporte de manière générale à une composition pharmaceutique et à une méthode améliorée permettant de prévenir, d'atténuer et de traiter le myélome multiple (MM) par l'administration à un individu nécessitant un tel traitement d'au moins un anticorps dirigé contre le récepteur du facteur croissance fibroblastique 3 (FGFR3). De manière plus particulière, ce(s) anticorps du FGFR3 provoquent l'apoptose des cellules de myélome exprimant un FGFR3 de type sauvage.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Treatment of b-cell malignancies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of b-cell malignancies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of b-cell malignancies will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1440754

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.